Pages that link to "Q84668999"

The following pages link to The NIMH-CATIE Schizophrenia Study: what did we learn? (Q84668999):

Displaying 28 items.

• Dendritic spine pathology in schizophrenia (Q26991935) (← links)
• Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study (Q27320151) (← links)
• Brain connectivity studies in schizophrenia: unravelling the effects of antipsychotics (Q30596256) (← links)
• Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications (Q33816182) (← links)
• Role of the axonal initial segment in psychiatric disorders: function, dysfunction, and intervention (Q34071914) (← links)
• Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. (Q34283319) (← links)
• Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy (Q34686544) (← links)
• Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China (Q35568945) (← links)
• A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report (Q36322256) (← links)
• Temporal effects of vascular endothelial growth factor and 3,5-cyclic monophosphate on blood-brain barrier solute permeability in vivo (Q36407801) (← links)
• Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future (Q36512458) (← links)
• Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders (Q36685572) (← links)
• Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks (Q37220392) (← links)
• Mortality Rates in Users of Typical and Atypical Antipsychotics: A Database Study in Poland (Q37297922) (← links)
• A drug utilization study of psychotropic drugs prescribed in the psychiatry outpatient department of a tertiary care hospital (Q37573174) (← links)
• Changes in physician antipsychotic prescribing preferences, 2002-2007. (Q37626797) (← links)
• Clinical Practice Guidelines for Management of Schizophrenia (Q37643030) (← links)
• Antipsychotic-induced akathisia in delirium: A systematic review. (Q38531305) (← links)
• Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review. (Q38664662) (← links)
• Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review (Q38674637) (← links)
• Evaluation of the Safety of Clozapine Use in Patients With Benign Neutropenia (Q38979539) (← links)
• Using model systems to understand errant plasticity mechanisms in psychiatric disorders (Q38992288) (← links)
• Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial (Q47565684) (← links)
• Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients (Q48288493) (← links)
• Internal, External, and Ecological Validity in Research Design, Conduct, and Evaluation (Q57123191) (← links)
• Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia (Q64060513) (← links)
• Preventing discrimination based on psychiatric risk biomarkers (Q88314938) (← links)
• The association between a free medicine program and functioning in people with schizophrenia: a cross-sectional study in Liuyang, China (Q94475302) (← links)